JRCT ID: jRCT1080224735
Registered date:19/06/2019
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 01/07/2019 |
Target sample size | 12 |
Countries of recruitment | Japan |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : Ixekizumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy |
---|---|
Secondary Outcome | safety efficacy |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | Eli Lilly Japan K.K. |
---|---|
Secondary Sponsor | - |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT03942042,JapicCTI-194811 |